Sorrento Collaborates with Celularity to Initiate the Development of Emergency Allogeneic Natural Killer Cell Therapy for Coronavirus Infection

 Sorrento Collaborates with Celularity to Initiate the Development of Emergency Allogeneic Natural Killer Cell Therapy for Coronavirus Infection

Sorrento Collaborates with Celularity to Initiate the Development of Emergency Allogeneic Natural Killer Cell Therapy for Coronavirus Infection

Shots:

  • The companies will utilize Celularity’s CYNK-001 as a potential novel therapy for the treatment and prevention of coronaviruses targeting mainly 2019-nCoV
  • Sorento will utilize its existing “state-of-the-art” cGMP cell therapy manufacturing facilities in California to augment Celularity’s new cGMP facility in New Jersey. The combined capacity will boost the scale-up and sustained production of the novel cell therapy
  • Celularity’s CYNK-001 is an allogeneic, off-the-shelf, placental-derived NK cell therapy. Additionally, Sorrento is in contact with scientists and local Chinese experts to discuss the clinical validation and logistics requirements to fast-track CYNK-001 available in China for coronavirus infection

Click here ­to­ read full press release/ article | Ref: Sorrento Therapeutics | Image:  Sorrento Therapeutics 

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post